Patent · US Active

Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof

US7906123B1 · kind B1 · utility

4Cited by

1References

17Claims

0Family size

Assignees

INSTITUT PASTEUR · FR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR

Inventors

Claude Leclerc · Paris, FR
Mohammed El-Idrissi · Azemmour, MA
Daniel Ladant · Cachan, FR
Cecile Bauche · Paris, FR
Peter Sebo · Praha, CZ
Jirina Loucka · Kladno, CZ
Radim Osicka · Praha, CZ

Key dates

Filing date	Mar 5, 2007
Grant date	Mar 15, 2011
Priority date	—
Expiry date	Jul 26, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/53
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to modified Bordetella adenylate cyclase toxins which are deficient for CD11b/CD18 binding and to their use in the preparation of pharmaceutical composition for the treatment of whooping cough and/or for the protection against Bordetella infection. The invention also relates to specific fragments of Bordetella adenylate cyclase comprising the CD11b/CD18 interaction domain and their use, especially for targeting a molecule of interest to CD11b expressing cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.